Xeris Biopharma Holdings (XERS) Change in Accured Expenses (2020 - 2026)

Xeris Biopharma Holdings (XERS) has 7 years of Change in Accured Expenses data on file, last reported at -$4.7 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 445.1% year-over-year to -$4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.7 million (down 294.18% YoY) and the FY2025 annual result came in at $3.3 million, up 408.4% from the prior year.
• Change in Accured Expenses eased to -$4.7 million in Q1 2026, from $1.9 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $15.4 million in Q4 2023 to a low of -$13.7 million in Q3 2023.
• A 5-year average of -$614117.6 and a median of $469000.0 in 2024 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses plunged 58305.26% — and 2023, when it soared 1950.33%.
• Tracing XERS's Change in Accured Expenses over 5 years: stood at $751000.0 in 2022, then soared by 1950.33% to $15.4 million in 2023, then plunged by 121.89% to -$3.4 million in 2024, then jumped by 156.91% to $1.9 million in 2025, then sank by 344.16% to -$4.7 million in 2026.
• The last three Change in Accured Expenses figures came in at -$4.7 million (Q1 2026), $1.9 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.